Press Release - Hd-innovation.de

For further information please
contact:
Anke zur Mühlen
Corporate Communication
+ 49 (0) 214 87632 22
+ 49 (0) 214 87632 90
a.zurmuehlen@biofrontera.com
Biofrontera AG
Hemmelrather Weg 201
D- 51377 Leverkusen, Germany
28 January 2008
News Release
Biofrontera expands its team with experienced marketing and
sales specialists
Leverkusen, Germany – Biofrontera AG (DSE: B8F) would like to announce
that at the beginning of this year its subsidiary company, Biofrontera
Pharma GmbH, was able to considerably strengthen its team by employing
Mrs. Dr. Anja Schürmann as Director of Marketing and Sales and Miss Dr.
Sabrina Narayanan as Medical-Scientific Expert.
Mrs. Dr. Anja Schürmann completed her biology degree at the University of
Bochum before obtaining her Doctorate in co-operation with the Bayerresearch
centre in Wuppertal. She started off her professional career as a
sales representative with the company Yamanouchi Pharma GmbH.
Subsequently she joined Hoyer-Madaus GmbH & Co. KG where she
started off as a product manager in the field of infection before being
promoted to director of marketing and sales in the business area of medical
devices and diagnostics in urology. In September 2004 Dr. Schürmann
switched to Galderma Laboratorium GmbH, a leading specialist in
dermatology. During this time she was responsible for the OTC products. In
her new position with Biofrontera she has taken over the responsibility and
management of marketing and sales. Biofrontera Pharma GmbH’s sales
force, which has been in place since April 2007, will benefit from her
extensive experience. The primary focuses of Dr. Schürmann’s activities
are on the one hand the strategic development of Biofrontera’s European
sales activities and on the other hand the consolidation of Biofrontera’s
market position. Biofrontera aims at positioning herself as competent
partner for dermatologists.
Miss Dr. Narayanan in her function as medical-scientific expert will support
the sales force in the field of medicine and science. Since 2004 she held a
similar position with Galderma Laboratorium GmbH and therefore brings
with her ideal requirements for the completion of her new task. After
starting out her professional career with GlaxoWelcome in the USA she
gained experience in the field of research and development at Merckle
Page 1

News Release
GmbH in Ulm and Direvo Biotech AG in Cologne. Dr. Narayanan
successfully completed her medical biotechnology degree at the University
of East London and obtained her PhD at the Rowett Research Institute in
Aberdeen, Scotland.
Dr. Narayanan will support the sales force, thereby enabling them to
answer and assist dermatologists even in medically and scientifically
challenging matters. Dr. Narayanan’s recruitment illustrates the important
progress made towards achieving Biofrontera’s goal in being accepted by
dermatologists as their medically & scientifically competent and reliable
partner.
Prof Dr. Lübbert, CEO of Biofrontera AG commented: “The expansion of
our management capacities in the area of marketing and sales was an
important goal for the beginning of 2008. This enables us to acquire further
products for the promotion by our sales force, hereby spreading the basis
of Biofrontera’s income”.
About Biofrontera AG
Biofrontera AG is specialized in the development of pharmaceutical
products in the area of dermatology. The company is characterized by a
broad, relatively close to the market product portfolio and a solid liquidity.
Biofrontera is listed in the regulated market of the Düsseldorf stock
exchange under the symbol B8F and the ISIN number DE0006046113.
www.biofrontera.com
This press release contains forward-looking statements based on the currently held
beliefs and assumptions of the management of Biofrontera AG, which are
expressed in good faith and, in their opinion, reasonable. Forward-looking
statements involve known and unknown risks, uncertainties and other factors,
which may cause the assumptions expressed or implied in this press release to be
faulty. Given these risks, uncertainties and other factors, recipients of this
document are cautioned not to place undue reliance on the forward-looking
statements. Biofrontera AG disclaims any obligation to update these forwardlooking
statements to reflect future events or developments.
Page 2